The stock of Cytori Therapeutics Inc (NASDAQ:CYTX) closed at $0.252 losing 3.04% in yesterday’s trading session. Cytori has today made the announcement regarding the reduction in fibrosis parameters in scar study. The Biomedical Advanced Research and Development Authority provided the required support towards making the study a major success.
One of the researchers in the study said, “The publication describes a study in which Adipose Derived Regenerative Cells (ADRCs), the active component of Cytori Cell Therapy™, were injected into deep partial thickness wounds in a porcine model, considered the gold standard preclinical model of hypertrophic scarring.”
He proceeded to reveal that six months later those wounds which were treated with ADRCs indicated reduction in parameters associated with hypertrophic scarring and that was brought into close comparison with the control wounds in a bid to establish the difference.
Parameters that were improved by treatment included skin hardness, vascularity, organization, and discoloration and it goes without saying that the company is making major progressive steps forward.
The temporal modulation of Interleukin-6 expression happens to be a major regulator in line with the various inflammatory responses. One thing that was quite evident was the fact that molecular analysis posed major implications in the whole process.
The preclinical study was a major success and its findings were incorporated into the design of the RELIEF clinical trial of Cytori Cell Therapy™. It is crucial to point out that BARDA played a huge role towards its overall success by even funding it.
The RELIEF trial will be seeking to carry out an assessment of the Cytori Cell Therapy among those patients struggling with substantial thermal burn injury. On top of that, it will also be seeking to carry of the evaluation of a number of the scar-related parameters by utilizing a series of approaches similar to those applied in the research.
Fibrosis happens to be a common factor in both scleroderma and burns and that is according to Chief Scientist at Cytori, Dr. John Fraser. He outlined that the preclinical study was consistent with several emerging studies and pulled along with a rather beneficial effect of Cytori’s ADRC technology in fibrotic disease
DISCLOSURE: The views and opinions expressed in this article are those of the authors, and do not represent the views of USmarketsDaily.com. Readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions. To read our full disclosure, please go to: